InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.245

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$153 Change of Share Registry Details 22 Sep 2023 12:34PM $0.620 $0.245 fallen by 60.48%
$153 Application for quotation of securities - PAR 13 Sep 2023 11:50AM $0.710 $0.245 fallen by 65.49%
$153 Corporate Governance Statement 1 Sep 2023 6:01PM $0.660 $0.245 fallen by 62.88%
$153 Appendix 4G 1 Sep 2023 6:01PM $0.660 $0.245 fallen by 62.88%
$153 Notice of release of escrowed securities 1 Sep 2023 12:21PM $0.640 $0.245 fallen by 61.72%
$153 Paradigm Accepted for Presentations at Major Conferences 1 Sep 2023 9:13AM $0.610 $0.245 fallen by 59.84%
$153 2023 Annual Report and Appendix 4E 25 Aug 2023 3:53PM $0.695 $0.245 fallen by 64.75%
$153 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 11:58AM $0.935 $0.245 fallen by 73.80%
$153 Study demonstrates Bene PPS is unique 27 Jul 2023 8:18AM $0.920 $0.245 fallen by 73.37%
$153 Application for quotation of securities - PAR 20 Jul 2023 1:03PM $0.995 $0.245 fallen by 75.38%
$153 Notice of release of escrowed securities 10 Jul 2023 2:14PM $0.985 $0.245 fallen by 75.13%
$153 PAR Reports Phase 3 Clinical Trial Update 4 Jul 2023 8:19AM $1.050 $0.245 fallen by 76.67%
$153 Notification of cessation of securities - PAR 29 Jun 2023 4:43PM $0.930 $0.245 fallen by 73.66%
$153 Primary and Secondary endpoints met in MPS I Trial 6 Jun 2023 12:28PM $0.833 $0.245 fallen by 70.57%
$153 iPPS shows 3-year equivalent durability in OA Canine Study 1 Jun 2023 8:21AM $0.860 $0.245 fallen by 71.51%
$153 Change of Director's Interest Notice - Fisher 22 May 2023 4:34PM $0.945 $0.245 fallen by 74.07%
$153 Change of Director's Interest Notice - Rennie 17 May 2023 4:26PM $0.980 $0.245 fallen by 75%
$153 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2023 2:24PM $1.010 $0.245 fallen by 75.74%
$153 PAR Phase 2 MPS VI clinical trial completes enrolment 28 Apr 2023 9:53AM $1.010 $0.245 fallen by 75.74%
$153 iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study 4 Apr 2023 9:29AM $1.435 $0.245 fallen by 82.93%
$153 Trading Halt 31 Mar 2023 9:21AM $1.435 $0.245 fallen by 82.93%
$153 PAR Poster Presentation to OARSI World Congress 2023 28 Mar 2023 8:18AM $1.355 $0.245 fallen by 81.92%
$153 Notification of cessation of securities - PAR 27 Mar 2023 4:08PM $1.350 $0.245 fallen by 81.85%
$153 NWR Virtual Healthcare Conference Presentation 22 Mar 2023 9:14AM $1.320 $0.245 fallen by 81.44%
$153 Paradigm to present at the NWR Virtual Healthcare Conference 21 Mar 2023 9:53AM $1.300 $0.245 fallen by 81.15%

251 - 275 of 741 results

Page 11 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.